Agilent and Roche sign NimbleGen agreement

Agilent Technologies and Roche have signed an agreement to provide continued service to NimbleGen microarray customers as Roche phases out its NimbleGen array production and services.

Researchers using NimbleGen microarrays for applications such as comparative genomic hybridisation, chromatin immunoprecipitation on chip, DNA methylation and gene expression can transition to Agilent arrays, effective immediately, with minimal disruption.

The similarities of the technologies and products from both companies reportedly provide an optimal transition path and the ability to run Agilent microarrays on the NimbleGen MS 200 microarray scanner.